That article is a significant acknowledgement of the contributions BIXT is making to the critical field of medicine for stroke treatments.
From the article:
BioXyTran is another rising star in the biopharmaceutical industry. The company is dedicated to the development of anti-necrosis drugs using the company’s lead product candidate, BXT-25, used as a resuscitative agent to treat Cardiac CereboVascular Accidents. The company is also foraying into regenerative medicine markets by developing a drug candidate named BXT 252 that has a plethora of wound healing applications. It is actively engaged in addressing unmet medical needs in field of hypoxia induced complications.
It lead drug candidate BXT-25 , a haemoglobin based polymer, that is 5000 times smaller than a red blood cell, can penetrate a blood-clot and reach the brain within 3 minutes. Its FDA approved OXYSENSE Technology allows it to measure oxygen delivery to brain in real-time. BXT-251 , another drug candidate aims to prolong extracorporeal circulation in cases of organ donations that can help them preserve organs for days rather than hours.
The company is at present raising funds for its clinical trials and is looking to build a robust intellectual property portfolio of patent applications and trademarks.
Mr. David Platt, the CEO of BioXyTran, a medicinal and PhD chemist with over 40 years of experience expressed confidence that the company will be able to keep up the positive momentum in 2019 and will be focussed on value creating clinical investigations, forging business development collaborations and planning and initiating an Investigational new drug registration with the FDA according to a press release.
The company has also filed a prospectus for a “Best Efforts No Minimum “offering of 10 million shares of common stock at $1 per share in November 2018.
